Get In Touch

Human proteins obtained through genetic engineering rather than from tissue samples have played a vital role in therapeutic medicines market. Advances in pharmacological understanding and pharmaceutical production have allowed continuous development of human proteins as a vital therapeutic option in variety of human diseases. From a clinical perspective, therapeutic proteins provide essential therapies in various life threatening disease such as diabetes, viral hepatitis, end-stage renal disease, clotting disorders and other metabolic disorders. Proteins as a part of the natural metabolism are synthesized by the living organism. Proteins play a significant role in carrying out vital body functions such as cell signaling, immune responses, cell adhesion, and the cell cycle. Industries such as biopharmaceutical industry, enzyme industry, and agriculture industry over a decade have been significantly benefited from native and recombinant proteins. In general therapeutic proteins include antibody-based drugs, bone morphogenetic proteins, FC fusion proteins, hormones, interleukins, and anticoagulants. Major application areas for these recombinant proteins include multiple sclerosis, dwarfism, anemia, rheumatoid arthritis, Crohn’s disease, diabetes and others.

Increasing investment on research activities and introduction of new protein therapeutics has significantly contributed in growth and development of recombinant therapeutic antibodies and proteins market. Moreover rising number of clinical trials in pharmaceutical industry have also contributed in growth and development of market in past few years. Owing to increased focus on developing innovative monoclonal antibodies (mAb), this segment is expected to dominate during the forecast period. Interestingly, although the recombinant therapeutic and proteins market is significantly smaller than overall pharmaceutical market yet the growth rate of the market is significantly higher than the overall pharmaceutical market. Restraint to the growth of the market includes lack of variety in formulations as most the recombinant antibodies and proteins can only be administered via injections. There are several problems associated with the administration of protein drug via injection such as it increases the overall cost of the treatment, need of trained caregiver during the course of treatment barring a few such as insulin and others. Additionally patent expiration of branded drugs and budget constraints are another major factor limiting the growth and exploration of application areas. 

Geographically the market is largely dominated by the developed economic regions such as North America and Europe owing to rapid growth of the biotechnology derived techniques in these two regions. Additionally significant research support in terms of infrastructure and funding has also driven recombinant therapeutic antibodies and proteins market in past one decade. Emerging markets such as Asia Pacific and Rest of the World market are expected to be the fastest growing market pertaining to developing economic scenario and increasing demand for therapeutics market. Owing to such reforms and growth in developing economic countries have successfully contributed in attracting prominent players to these regions as a strategy to increase customer base and business expansion. Major branded monoclonal antibodies in the market include Rituxan (rituxumab), Synagis (Palivizumab), Campath (Alemtuzumab), Erbitux (Cetuximab). Whereas branded therapeutic proteins in the market comprises Levemir (Datemir insulin), Neulasta (PEG-Filgrastim), Enbrel (Etanercept), Ontak (rIL2-diptheria toxin) and others. Recombinant proteins currently in clinical trial phase include AERAS-404, Interferon alpha2a Fusion Protein, Anakinra, Aldesleukin and others.

Some of the prominent players operating in the global recombinant therapeutic antibodies and protein market include Bristol-Myers Squibb, Celldex Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Schering AG, Johnson & Johnson and others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Recombinant Therapeutic Antibodies Proteins Market

Pre Book